Lexicon Pharmaceuticals to sell stock in registered direct offering

By Devika Patel

Knoxville, Tenn., Oct. 7 - Lexicon Pharmaceuticals, Inc. will sell 11,087,387 common shares to Invus, LP in a registered direct offering, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission. The company also is selling 16,412,613 shares via underwriters Morgan Stanley and Thomas Weisel Partners LLC in a public sale.

Based in the Woodlands, Texas, Lexicon develops treatments for human diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.